Haemonetics

Haemonetics Financing Cash Flow

The Net Financing Cash Flow of Haemonetics (HAE) as of Oct 20, 2026 is -178.46 M USD. In the previous year, Net Financing Cash Flow was 108.82 M USD — a change of -264.00% (lower).

Financing Cash Flow

-178.46 MUSD

YoY

-264.00%

Last updated:

Net Financing Cash Flow of Haemonetics is 2026 -178.46 M USD. Net Financing Cash Flow of Haemonetics was 2025 108.82 M USD. It decreases by -264.00% lower compared to the previous year.

The Haemonetics Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2019
-50.63 M USD
Jan 1, 2020
-131.21 M USD
Jan 1, 2021
367.45 M USD
Jan 1, 2022
-15.75 M USD
Jan 1, 2023
-100.36 M USD
Jan 1, 2024
38.16 M USD
Jan 1, 2025
108.82 M USD
Jan 1, 2026
-178.46 M USD
The Haemonetics Financing Cash Flow history
YEARFinancing Cash FlowYoY
-178.46 MUSD-264.00%
108.82 MUSD+185.18%
38.16 MUSD-138.02%
-100.36 MUSD+537.27%
-15.75 MUSD-104.29%
367.45 MUSD-380.05%
-131.21 MUSD+159.16%
-50.63 MUSD-58.03%
-120.64 MUSD+99.70%
-60.41 MUSD-3.53%
-62.62 MUSD+88.85%
-33.16 MUSD+60.19%
-20.70 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Haemonetics Stock analysis

What does Haemonetics do? Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Haemonetics stock

Net Financing Cash Flow of Haemonetics is -178.46 M USD in 2026.

Net Financing Cash Flow of Haemonetics changed from 108.82 M USD to -178.46 M USD, representing a -264.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Haemonetics since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Haemonetics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Haemonetics

All Key Metrics — Haemonetics